Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Accumulated Expenses (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Accumulated Expenses for 8 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses fell 60.61% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.3 million, a 60.61% decrease, with the full-year FY2024 number at $5.2 million, up 232.82% from a year prior.
  • Accumulated Expenses was $1.3 million for Q3 2025 at Precision Biosciences, down from $2.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $6.8 million in Q4 2021 to a low of $656000.0 in Q1 2024.
  • A 5-year average of $3.1 million and a median of $3.2 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: plummeted 72.99% in 2022, then surged 232.82% in 2024.
  • Precision Biosciences' Accumulated Expenses stood at $6.8 million in 2021, then tumbled by 72.99% to $1.8 million in 2022, then decreased by 14.78% to $1.6 million in 2023, then soared by 232.82% to $5.2 million in 2024, then plummeted by 74.97% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Accumulated Expenses are $1.3 million (Q3 2025), $2.4 million (Q2 2025), and $1.3 million (Q1 2025).